Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
Rhea-AI Summary
Telix (ASX:TLX, NASDAQ:TLX) announced that Managing Director and Group CEO Dr. Christian Behrenbruch will present at the William Blair 46th Annual Growth Stock Conference in Chicago on June 2, 2026, and the Jefferies Global Healthcare Conference in New York on June 3, 2026. Both sessions will be available via live webcast on Telix’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – TLX
In the May 27 session, TLX gained 1.78%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 18 | Phase 1 enrolment update | Positive | -1.3% | IPAX-2 TLX101-Tx Phase 1 completed enrolment with no dose-limiting toxicities. |
| May 15 | Collaboration announcement | Positive | -2.8% | Letters of intent for PSMA-PET imaging collaborations in localized prostate cancer. |
| May 04 | Diagnostic data publication | Positive | -1.0% | Phase 3 ZIRCON TLX250-Px data showed strong PPV, sensitivity and specificity. |
| Apr 30 | MAA acceptance | Positive | +2.4% | European MAA for TLX101-Px accepted, entering 210-day assessment period. |
| Apr 29 | Phase 2 trial data | Positive | +5.5% | OPTIMAL-PSMA TLX597-Tx Phase 2 data highlighted favorable tumor vs organ uptake. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally been positive clinically and regulatorily, yet TLX has shown mixed reactions, including several instances where the stock fell on seemingly constructive updates.
Over the past two months, Telix has reported multiple clinical and regulatory milestones. These include completion of enrolment in the Phase 1 IPAX-2 TLX101-Tx glioblastoma study with no dose-limiting toxicities, collaborations around PSMA-PET imaging agents Gozellix and Illuccix, and strong Phase 3 ZIRCON diagnostic performance data for TLX250-Px. The company also secured European MAA acceptance for TLX101-Px and presented encouraging OPTIMAL-PSMA Phase 2 data for TLX597-Tx. Today’s conference participation update follows this steady cadence of clinical and partnering news.
Key Terms
psma-pet imaging medical
pet/ct medical
maa regulatory
form 6-k regulatory
convertible bonds financial
radiopharmaceutical medical
pet imaging medical
transitional pass-through status regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
MELBOURNE, Australia and INDIANAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will participate in the upcoming William Blair 46th Annual Growth Stock Conference in Chicago, IL and in the Jefferies Global Healthcare Conference in New York, NY.
Presentation details:
William Blair 46th Annual Growth Stock Conference
Date: June 2, 2026
Time: 8:00 a.m. CDT (9:00 a.m. EDT, 11:00 p.m. AEST)
Jefferies Global Healthcare Conference
Date: June 3, 2026
Time: 11:40 a.m. EDT (1:40 a.m. AEST, June 4)
Each session will be webcast live, and accessible through Telix’s Investor Relations website.
For more information including how to register, please visit: https://ir.telixpharma.com/events-presentations.
About Telix Pharmaceuticals Limited
Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
| Telix Investor Relations (Global) Ms. Kyahn Williamson SVP Investor Relations and Corporate Communications kyahn.williamson@telixpharma.com | Telix Investor Relations (Australia) Ms. Charlene Jaw Associate Director Investor Relations charlene.jaw@telixpharma.com | Telix Investor Relations (U.S.) Ms. Annie Kasparian Director Investor Relations and Corporate Communications annie.kasparian@telixpharma.com |
| Media Contact Eliza Schleifstein 917.763.8106 (Mobile) Eliza@schleifsteinpr.com | ||
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
